{
    "id": 12689,
    "name": "acoustic neuroma",
    "source": "DOID",
    "definition": null,
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        
    ],
    "termId": "DOID:12689",
    "evidence": [
        {
            "id": 2241,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Avastin (bevacizumab) improved hearing in 57% (13/23) and reduced tumor size in 55% (17/31) vestibular schwannoma patients with NF2 mutations (PMID: 22805104).",
            "molecularProfile": {
                "id": 3109,
                "profileName": "NF2 mutant"
            },
            "therapy": {
                "id": 667,
                "therapyName": "Bevacizumab",
                "synonyms": null
            },
            "indication": {
                "id": 12689,
                "name": "acoustic neuroma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2824,
                    "pubMedId": 22805104,
                    "title": "Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22805104"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 2242,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Caprelsa (vandetanib) inhibited EGFR and VEGFR activity, induced apoptosis, and reduced tumor growth in human and mouse cell line xenograft models of vestibular schwannoma deficient in NF2 (PMID: 20406973).",
            "molecularProfile": {
                "id": 6530,
                "profileName": "NF2 loss"
            },
            "therapy": {
                "id": 953,
                "therapyName": "Vandetanib",
                "synonyms": null
            },
            "indication": {
                "id": 12689,
                "name": "acoustic neuroma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2825,
                    "pubMedId": 20406973,
                    "title": "Anti-vascular endothelial growth factor therapies as a novel therapeutic approach to treating neurofibromatosis-related tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20406973"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2243,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, Tarceva (ertlotinib) treatment resulted in prolonged stable disease in 30% (3/10) of patients with NF2-related vestibular schwannoma (PMID: 20736812).",
            "molecularProfile": {
                "id": 3109,
                "profileName": "NF2 mutant"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 12689,
                "name": "acoustic neuroma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 2826,
                    "pubMedId": 20736812,
                    "title": "Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20736812"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2244,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with Tasigna (nilotinib) inhibited PDGFR activation, and resulted in decreased proliferation and increased apoptosis of NF2-deficient vestibular schwannoma cells in culture (PMID: 22745749).",
            "molecularProfile": {
                "id": 6530,
                "profileName": "NF2 loss"
            },
            "therapy": {
                "id": 829,
                "therapyName": "Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 12689,
                "name": "acoustic neuroma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2827,
                    "pubMedId": 22745749,
                    "title": "Investigation of the in vitro therapeutic efficacy of nilotinib in immortalized human NF2-null vestibular schwannoma cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22745749"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2245,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, treatment with Tykerb (lapatinib) resulted in objective volumetric response in 23.5% (4/17) and prolonged stable disease in 17.6% (3/17) of patients with NF2-related vestibular schwannoma (PMID: 22844108).",
            "molecularProfile": {
                "id": 6530,
                "profileName": "NF2 loss"
            },
            "therapy": {
                "id": 787,
                "therapyName": "Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 12689,
                "name": "acoustic neuroma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2828,
                    "pubMedId": 22844108,
                    "title": "Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22844108"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        }
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT03095248",
            "title": "Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 913,
                    "therapyName": "Selumetinib",
                    "synonyms": null
                }
            ]
        }
    ]
}